Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Hypertriglyceridemia
Interventions: Epanova, Olive Oil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 58
States / cities: Huntsville, Alabama • Vestavia Hills, Alabama • Anaheim, California + 49 more

Conditions: HCV Infection
Interventions: placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 48
States / cities: Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more

Conditions: Moderate to Severe Opioid-use Disorder
Interventions: Transmucosal Buprenorphine, Extended-release Buprenorphine; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 785 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 28
States / cities: Garden Grove, California • Panorama City, California • San Diego, California + 21 more

Conditions: Diabetic Autonomic Neuropathy
Interventions: Cycloset, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 30 Years to 80 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Nulliparous Women Who Scheduled for Labor Induction, Pregnancy
Interventions: Sequential Cervical Ripening, Inpatient Combined Cervical Ripening; Combination Product
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Infant, Newborn, Disease, Genetic Disease
Interventions: Neonate WGS Testing; Diagnostic Test
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: Up to 1 Year
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Insulin aspart, Supplemental insulin aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Metformin, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Tuberculosis
Interventions: Epistem Genedrive® and MolBio Truenat™; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle, intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Psoriasis
Interventions: Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy
Interventions: ketogenic diet; Other
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: Continuing Medical Education Events (CME), Trial Connect Portal, Clinical Trial Newsletters, Implicit Bias Training, Recruitment Dashboard, Portfolio Profiler, Eligibility Calculator, Clinical Trial Education Sessions (Community Residents Only), ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients), New Patient Information (Moffitt Patients Only), No Intervention; Behavioral · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7,649 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Adipose Tissue, Brown, Adipose Tissue, Obesity
Interventions: Fat biopsy, Blood sampling, Blood sample for DNA analysis; Procedure · Diagnostic Test · Genetic
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Suicidal Depression (ASD)
Interventions: Subanesthetic dose intravenous ketamine (KET), Electroconvulsive therapy (ECT); Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Baltimore, Maryland • Belmont, Massachusetts + 6 more

Conditions: Healthy Participants
Interventions: Laroprovstat/ezetimibe FCDP, Laroprovstat STP, Ezetimibe STP, Laroprovstat/ezetimibe FCDP-slow variant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Alzheimer Disease and Related Dementias (ADRD)
Interventions: Passive Digital Marker for screening for ADRD; Other
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older
Enrollment: 5,325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Crohn Disease
Interventions: Soy based diet, Non-soy based diet; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metabolic Syndrome, Postmenopausal Symptoms
Interventions: Time-Restricted Feeding (TRF); Behavioral
Lead sponsor: Julie Pendergast; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HER2-positive Breast Cancer
Interventions: Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: Behavior and Behavior Mechanisms, Communication
Interventions: Door-In-The-Face Technique, Foot-In-The-Door Technique; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cleft Lip and Palate
Interventions: Maxillary Protraction, Orthognathic Surgery; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 11 Years to 21 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • Seattle, Washington

Conditions: Rapid HIV Screening
Interventions: A: Nontargeted rapid HIV screening, B: Enhanced targeted rapid HIV screening, C: Traditional targeted rapid HIV screening; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 16 Years and older
Enrollment: 76,235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Oakland, California • Denver, Colorado • Baltimore, Maryland + 1 more

Search by objective public record fields.

Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

Ripening Approaches for Prompt Induction and Delivery - Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery (RAPID-DS)

Genome Sequencing in the Intensive Care Unit Population

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Dapagliflozin Effects on Epicardial Fat

Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests

The Effect of Brain Anatomy on the Efficacy of Brain Stimulation Therapy

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)

The Physiology of Human Brown Adipose Tissue

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults

Digital Detection of Dementia (D Cubed) Studies: D2

A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients

Circadian Rhythms in Postmenopausal Women

Fasting on Newly Diagnosed Breast Cancer

COVID-19 Resource Offers Among Rent and Utility Assistance Applicants in St. Louis

Clinical Effectiveness of Late Maxillary Protraction for Cleft Lip and Palate

The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial